<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8150">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01792804</url>
  </required_header>
  <id_info>
    <org_study_id>Uni-Koeln-1400</org_study_id>
    <secondary_id>2013-000577-77</secondary_id>
    <nct_id>NCT01792804</nct_id>
  </id_info>
  <brief_title>Staphylococcus Aureus Bacteremia Antibiotic Treatment Options</brief_title>
  <acronym>SABATO</acronym>
  <official_title>Early Oral Switch Therapy in Low-risk Staphylococcus Aureus Bloodstream Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cologne</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increasing resistance to antibiotic agents has been recognized as a major health problem
      worldwide that will even aggravate due to the lack of new antimicrobial agents within the
      next decade [1]. This threat underscores the need to maximize clinical utility of existing
      antibiotics, through more rational prescription, e.g. optimizing duration of treatment.

      Staphylococcus aureus bloodstream infection (SAB) is a common disease with about 200,000
      cases occurring annually in Europe [2]. A course of at least 14 days of intravenous
      antimicrobials is considered standard therapy [3-5] in &quot;uncomplicated&quot; SAB. This relatively
      long course serves to prevent SAB-related complications (such as endocarditis and vertebral
      osteomyelitis) that may result from hematogenous dissemination to distant sites. However,
      there is insufficient evidence that a full course of intravenous antibiotic therapy is
      always required in patients with a low risk of SAB-related complications.

      In a multicenter, open-label, randomized controlled trial we aim to demonstrate that an
      early switch from intravenous to oral antimicrobial therapy is non-inferior to a
      conventional 14-days course of intravenous therapy regarding efficacy and safety. An early
      switch from intravenous to oral therapy would provide several benefits such as earlier
      discharge, fewer adverse reactions associated with intravenous therapy, increased quality of
      life, and cost savings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. WHO. WHO Global Strategy for Containment of Antimicrobial Resistance.: World Health
           Organization, 2001.

        2. Kern WV. Management of Staphylococcus aureus bacteremia and endocarditis: progresses
           and challenges. Curr Opin Infect Dis 2010;23(4):346-58.

        3. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the
           prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA)
           infections in the UK. J Antimicrob Chemother 2006;57(4):589-608.

        4. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious
           Diseases Society of America for the treatment of methicillin-resistant Staphylococcus
           aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-55.

        5. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and
           management of intravascular catheter-related infection: 2009 Update by the Infectious
           Diseases Society of America. Clin Infect Dis 2009;49(1):1-45.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>SAB-related complications</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>S. aureus bloodstream infection-related complications (relapsing SAB, deep-seated infection with S. aureus, or attributable mortality) within 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>14, 30, and 90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Survival at 14, 30, and 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of intravenous therapy</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complications of intravenous therapy, such as thrombophlebitis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clostridium difficile associated diarrhea (CDAD)</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clostridium difficile associated diarrhea (CDAD)</description>
  </other_outcome>
  <other_outcome>
    <measure>AEs and SAEs</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">430</enrollment>
  <condition>Staphylococcus Aureus Bloodstream Infection</condition>
  <arm_group>
    <arm_group_label>Orally administered antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First choice (MRSA and MSSA): trimethoprim-sulfamethoxazole, or Second choice (MSSA): clindamycin, or Second choice (MRSA): linezolid administered for 7-9 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First choice (MSSA): flucloxacillin [Spain: cloxacillin], or cefazolin or Second choice (MSSA): vancomycin, or First choice (MRSA): vancomycin, or Second choice (MRSA): daptomycin administered for 7-9 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim-Sulfamethoxazole</intervention_name>
    <arm_group_label>Orally administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin</intervention_name>
    <arm_group_label>Orally administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <arm_group_label>Orally administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flucloxacillin</intervention_name>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cloxacillin</intervention_name>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin</intervention_name>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at least 18 years

          -  Not legally incapacitated

          -  Written informed consent from the trial subject has been obtained

          -  Blood culture positive for S. aureus

          -  At least one negative follow-up blood culture obtained within 48-72 hours after the
             start of adequate therapy

          -  Five to seven full days of appropriate i.v. antimicrobial therapy administered prior
             to randomization.

        Exclusion Criteria:

          -  Polymicrobial bloodstream infection

          -  Recent history of prior S. aureus bloodstream infection

          -  In vitro resistance of S. aureus to all oral or all i.v. study drugs

          -  Contraindications for all oral or all i.v. study drugs

          -  Signs and symptoms of complicated SAB as judged by an ID physician, such as
             deep-seated focus,septic shock, prolonged bacteremia, fever on two occasions within
             48h before randomization,presence of non-removable foreign body.

          -  Failure to remove (within 4 days) any intravascular catheter, which is present when
             first positive blood culture was drawn

          -  Severe liver disease

          -  End-stage renal disease

          -  Severe immunodeficiency (e.g. primary immunodeficiency disorders, neutropenia CD4+
             T-cell count &lt;200/µl in HIV-positive patients, high-dose steroid therapy, recent
             hematopoietic stem cell transplantation, solid organ transplant)

          -  &quot;Do not resuscitate&quot;-order or life expectancy &lt; 3 months

          -  Inability to take oral drugs

          -  Injection drug user

          -  Expected low compliance with drug regimen

          -  Participation in other interventional trials

          -  Pregnant women and nursing mothers
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Achim J Kaasch, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Achim J Kaasch, MD</last_name>
    <phone>+4922147832100</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian M Bernasch</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sebastian Lemmen, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Keikawus Arastéh, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Cologne</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernasch</last_name>
      <email>christian.bernasch@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Gerd Fätkenheuer, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frankfurt</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christoph Stephan, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Winfried V Kern, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tobias Welte, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthias Pletz, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krefeld</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Katrin Kösters, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leverkusen</name>
      <address>
        <city>Leverkusen</city>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefan Reuter, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan Rupp, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bernd Salzberger, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Georg Härtner, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan T.M. van der Meer, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Breda</name>
      <address>
        <city>Breda</city>
        <zip>4814 CK Breda</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan Kluytmans, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sander van Assen, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tilburg</name>
      <address>
        <city>Tilburg</city>
        <zip>5022GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jan Kluytmans, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marc Bonten, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barcelona I</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alex Soriano, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barcelona II</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benito Almirante, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sevilla</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jesus Rodríguez-Baño, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sevilla II</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José Cisneros, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 24 H</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Turner, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 16, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cologne</investigator_affiliation>
    <investigator_full_name>Gerd Fätkenheuer</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Staphylococcus aureus</keyword>
  <keyword>Bloodstream infection</keyword>
  <keyword>Oral switch</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin-2-phosphate</mesh_term>
    <mesh_term>Cloxacillin</mesh_term>
    <mesh_term>Floxacillin</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Daptomycin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim-Sulfamethoxazole Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
